Condition (MeSH)
Bankart Lesions
ClinicalTrials.gov lists 13 trials for Bankart Lesions or a narrower condition beneath it. Smith & Nephew, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Bankart Lesions itself; the rest are tagged with a narrower condition beneath it.
When did Bankart Lesions trials start? (10)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 1 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 3 |
| 2016 | 1 |
| 2014 | 1 |
| 2011 | 1 |
| 2010 | 1 |
| 2009 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 13 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Bankart Lesions trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 1 |
| Not applicable | 7 |
| Observational | 5 |
How many Bankart Lesions trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Completed | 9 |
| Unknown status | 3 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Bankart Lesions trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Smith & Nephew, Inc. | 2 |
| Keller Army Community Hospital | 1 |
| Tel-Aviv Sourasky Medical Center | 1 |
| Zimmer Biomet | 1 |
Which serious adverse events do Bankart Lesions trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Biceps tear/tendon rupture | 5 | 1 |
| PAIN | 3 | 1 |
| Bone fracture | 2 | 1 |
| CELLULITIS | 2 | 1 |
| Hip pain | 2 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Bankart Lesions? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Arthroscopic Bankart repair using trans-glenoid double-loaded grand knots versus double-loaded suture anchors; is there a difference? a randomized controlled study. | BMC musculoskeletal disorders | 2025 | Yes |
| Predictors of Bone Loss in Anterior Glenohumeral Instability. | The American journal of sports medicine | 2023 | Yes |
| Recurrence in traumatic anterior shoulder dislocations increases the prevalence of Hill-Sachs and Bankart lesions: a systematic review and meta-analysis. | Knee surgery, sports traumatology, arthroscopy : official journal of the ESSKA | 2022 | Yes |
| Risk factors for recurrence after Bankart repair: a systematic review and meta-analysis. | Journal of orthopaedic surgery and research | 2022 | Yes |
| Mid-Term outcomes following fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill Sachs lesion: a case series. | BMC musculoskeletal disorders | 2021 | Yes |
Showing 5 of 11 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: drugs tested, prevalence, rare-disease identity, and sub-conditions in mesh.